Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-23-009770
Filing Date
2023-03-24
Accepted
2023-03-24 16:59:02
Documents
14
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A omga-20221231.htm   iXBRL 10-K/A 117882
2 EX-31.1 omga-ex31_1.htm EX-31 20260
3 EX-31.2 omga-ex31_2.htm EX-31 19446
  Complete submission text file 0000950170-23-009770.txt   367643

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT omga-20221231_lab.xml EX-101.LAB 28228
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT omga-20221231.xsd EX-101.SCH 2683
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT omga-20221231_pre.xml EX-101.PRE 18971
8 EXTRACTED XBRL INSTANCE DOCUMENT omga-20221231_htm.xml XML 10598
Mailing Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140
Business Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-40657 | Film No.: 23760596
SIC: 2836 Biological Products, (No Diagnostic Substances)